PRISMRA‑R performed/billed by Scipher Medicine; orderable through Quest
Use
PrismRA is a blood‑based molecular signature response classifier (MSRC) designed to predict inadequate response to tumor necrosis factor inhibitor (TNFi) therapy in patients with rheumatoid arthritis (RA). It analyzes RNA transcripts and anti‑CCP antibody levels, combining molecular and clinical features, to guide therapy decisions and avoid ineffective TNFi treatment by identifying likely non‑responders prior to therapy initiation. Physicians receive a personalized score report to inform choice of alternative effective treatments.
Special Instructions
Performed and billed by Scipher Medicine, but orderable through Quest Diagnostics. Collection and logistics are supported by Quest’s network of patient access points; specimen collection involves routine blood draw. Patients and providers order via Quest, but testing and billing handled by Scipher Medicine.
Limitations
High score indicates likelihood of inadequate response to TNFi therapy, but low score does not guarantee treatment success. Predictive accuracy is based on classifier performance; patient-specific factors beyond molecular and clinical signature may influence outcomes.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided